BioThrust

𝗪𝗵𝗮𝘁 𝗶𝘀 𝘁𝗵𝗲 𝗸𝗟𝗮 𝗿𝗮𝘁𝗲, 𝗮𝗻𝗱 𝘄𝗵𝘆 𝗶𝘀 𝗶𝘁 𝗶𝗺𝗽𝗼𝗿𝘁𝗮𝗻𝘁 𝗳𝗼𝗿 𝗯𝗶𝗼𝗿𝗲𝗮𝗰𝘁𝗼𝗿𝘀? 🫧 In bioprocessing, 𝘬𝘓𝘢—the volumetric oxygen transfer coefficient—is critical. It measures the efficiency of oxygen transfer from gas to liquid in a bioreactor. A high 𝘬𝘓𝘢 rate means a bioreactor can deliver more oxygen to cells precisely when and where it’s needed, supporting faster and more efficient cell culture processes at larger scales. 📈 Our Membrane Stirrer offers 15x the surface area of classic headspace aeration at 2L, enabling significantly greater gas transfer while minimizing shear forces. By optimizing low-shear 𝘬𝘓𝘢 rates, we ensure that sensitive cells grow consistently and predictably, even in commercial-scale systems of up to 200L. All without the need for (external) bubble aeration! In the attached graph, you can see data comparing tip speed and 𝘬𝘓𝘢 to conventional systems!💡 #BioThrust #Bioreactor #kLa #Celltherapy

𝗘𝘅𝗰𝗶𝘁𝗶𝗻𝗴 𝗽𝗲𝗼𝗽𝗹𝗲 𝗻𝗲𝘄𝘀: 𝗪𝗲𝗹𝗰𝗼𝗺𝗲 𝗙𝗮𝗯𝗶𝗲𝗻! 👋 We are elated to introduce Fabien M. as our Strategic Avisor!  With his more than 15 years of expertize in the industrialization of cell and gene therapies across multiple leading biotech firms, Fabien will play a pivotal role in driving our mission forward—making cell therapies affordable for everyone! 💪 Please join us in welcoming him to the Biothrust family! 🙌 #BioThrust #Biotechinnovation #WelcomeFabien #StrategicGrowth

𝗢𝗽𝘁𝗶𝗺𝗶𝘇𝗲 𝗢𝗻𝗰𝗲: 𝗦𝗰𝗮𝗹𝗲 𝗪𝗵𝗲𝗻 𝗬𝗼𝘂 𝗡𝗲𝗲𝗱 𝗜𝘁! 🛫 When choosing a bioreactor for cell therapy manufacturing, scalability may not be the first thing you think about, but it will make or break a production process down the line! And, as far as we are concerned, 𝘴𝘤𝘢𝘭𝘢𝘣𝘪𝘭𝘪𝘵𝘺 requires 𝘱𝘳𝘦𝘥𝘪𝘤𝘵𝘢𝘣𝘪𝘭𝘪𝘵𝘺. ✅ 𝗛𝗼𝘄 𝗱𝗼 𝘄𝗲 𝗮𝗰𝗵𝗶𝗲𝘃𝗲 𝘁𝗵𝗶𝘀? The secret to true scalability lies in the consistent environment our bioreactor design provides, regardless of vessel size. With our innovative Membrane Stirrer, we've eliminated the need for external (bubble) aeration, ensuring uniform gas transfer conditions throughout. Plus, the symmetrical design maintains predictable mixing patterns as you scale up. Unfortunately, designing such a bioreactor requires quite a lot of CFD simulation and measurement, keeping our engineers Moritz, Florian and Lukas busy 👨🔬. But at least we also get some nice pictures out of it! 📸 Important: The shear rates below were calculated at very high RPMs, optimized for microbiological processes, and are therefore quite high. Low-shear cell therapy specific simulations at <100 RPM will follow shortly! #BioThrust #Bioreactor #Scaleup #Celltherapy

Very interesting post by our CEO Patrick Bongartz that shows the difference in foam formation between classic bubble-aeration and our Membrane Stirrer. No foam, no problems! 😆

𝗢𝘃𝗲𝗿 𝟯𝟱 𝗗𝗮𝘆𝘀 𝗼𝗳 𝗦𝘂𝗰𝗰𝗲𝘀𝘀𝗳𝘂𝗹 𝗟𝘂𝗻𝗴 𝗢𝗿𝗴𝗮𝗻𝗼𝗶𝗱 𝗖𝘂𝗹𝘁𝗶𝘃𝗮𝘁𝗶𝗼𝗻 𝗶𝗻 𝗦𝘂𝘀𝗽𝗲𝗻𝘀𝗶𝗼𝗻 📅 Respiratory diseases are among the leading causes of mortality worldwide, imposing a significant medical and financial burden. In collaboration with Prof. Dr. Diana Klein & lab at the Universitätsmedizin Essen Hospital, we have developed a 2L proof-of-concept for a scalable lung organoid cultivation process. Such organoids pave the way for advanced in-vitro models, offering new insights into respiratory conditions. Are you working with lung or other organoids? Explore our application notes or reach out to us directly! #BioThrust #Organoids #iPSC

𝗛𝗼𝘄 𝗱𝗼𝗲𝘀 𝘁𝗵𝗲 𝗕𝗶𝗼𝗧𝗵𝗿𝘂𝘀𝘁 𝗖𝗼𝗺𝗳𝘆𝗖𝗲𝗹𝗹 𝘄𝗼𝗿𝗸? 🧐 We often hear, “Your bioreactor looks cool! How does it work?” and we're always excited to share the details! Let’s dive in. 🎯 1. Our proprietary Membrane Stirrer combines aeration and mixing into one sleek component, at any scale. The blade-like design creates gentle circular flow patterns at both the top and bottom of the stage, ensuring uniform, low-shear mixing of media. 2. The dense hollow fibers that make up the membrane are continuously flushed with gas. Since these fibers have no pores, gas molecules diffuse through the molecular structure, facilitating extremely efficient bubble-free gas transfer. Interested in learning more? Visit our website or contact us directly! #BioThrust #Innovation #Bioreactor #Celltherapy

𝗙𝗿𝗮𝗻𝗸𝗲𝗻𝘀𝘁𝗲𝗶𝗻 𝗦𝗰𝗶𝗲𝗻𝗰𝗲: 𝗚𝗿𝗼𝘄𝗶𝗻𝗴 𝗕𝗲𝗮𝘁𝗶𝗻𝗴 𝗛𝗲𝗮𝗿𝘁𝘀 𝗳𝗿𝗼𝗺 𝗦𝗰𝗿𝗮𝘁𝗰𝗵! 🧪💓🎃 In the spirit of Halloween, we’re excited to share some fascinating "Frankenstein science" (as Patrick always calls it) from our collaboration with Kurt Pfannkuche & lab at the University of Cologne. To advance organoid-based heart therapies, we seeded over 200,000 embryoid bodies in our 2L bioreactor. After just 7 days of differentiation, we generated more than 200 million functional cardiomyocytes (picture below) that actually started beating, just like real hearts! Spooky, isn’t it? Are you working with cardiomyocytes or other organoids? Explore our application notes linked below or reach out to us directly to learn more! 👉 https://lnkd.in/edrKZaTf #BioThrust #Organoids #Cardiomyocytes #Halloween #iPSC

StartupValley Magazine hat ein tolles Interview mit uns geführt, welches heute veröffentlicht wurde. Wir sprechen über unsere #Vison, aber auch über ganz konkrete Themen wie #Wettbewerb, #Herausforderungen und unsere #Strategie. Herzliche Einladung, uns auch hier Feedback zu geben - was denken Sie über unsere Entwicklung und unsere Ziele? 🤓

Small recap of the last two weeks in Jena at the GSCN and in Boston at the iPSC Drug Development & Manufacturing Summit: We made a bunch of new connections in the US and glad to see the ongoing demand on our solutions. Thanks to Dr. Dennis Stibane and IKA – Laboratory, Analytical and Process Technology for the support with a demo controller! And big applause for our new friends Bryan Wang, Romane Gohier and Arjavi Vyas for the nice sightseeing tour! We felt very welcome in Bean city!

Back to the US 🌎 ! As announced, we are attending the 4th Annual iPSC Drug Development & Manufacturing Summit to present our latest lab-results regarding these cell-types. We want to accelerate process scale-up with those sensitive cells. Come around at Booth #6 to discuss with Patrick Bongartz and Paul Alexander Fliser about your opportunities to leverage your process to the next stage. 📈